Scholarlink

<p>Hepatoblastoma is the most common malignant liver tumor of embryonic origin in children; however, its underlying etiology remains unclear. N1-methyladenosine (m<sup>1</sup>A) modification is widely found in various human tissues and has been demonstrated to regulate tumorigenesis, but no studies have explored the role of <i>ALKBH1</i> in the development of hepatoblastoma. We genotyped three <i>ALKBH1</i> gene polymorphisms (rs1048147 C &gt; A, rs6494 T &gt; A, and rs176942 A &gt; G) via the TaqMan method for 313 patients with hepatoblastoma and 1446 healthy subjects, after which the odds ratios (ORs), 95% confidence intervals (CIs), and <i>P</i> values for each polymorphism were calculated. We found that all the three polymorphisms were significantly associated with hepatoblastoma susceptibility. The rs1048147 C &gt; A was shown to reduce hepatoblastoma risk (adjusted OR = 0.72, 95% CI = 0.56–0.92, <i>P</i> = 0.009) under dominant model, whereas rs6494 T &gt; A (adjusted OR = 6.17, 95% CI = 1.37–27.37, <i>P</i> = 0.018) and rs176942 A &gt; G (adjusted OR = 2.12, 95% CI = 1.22–3.69, <i>P</i> = 0.008) significantly increased hepatoblastoma risk under recessive model. Stratified analysis indicated that the rs1048147 CA/AA genotype decreased hepatoblastoma risk in children aged ≥ 17 months, females, and those with clinical stages I + II, whereas the rs176942 GG genotype increased the risk of hepatoblastoma in females. In addition, carriers of 2–3 risk genotypes had higher risk of tumor development, specifically among children aged ≥ 17 months, males, and those diagnosed with clinical stages I–II disease. Finally, eQTL analysis revealed that the three polymorphisms were associated with the expression levels of <i>ADCK1</i>, <i>SNW1</i>, and <i>SLIRP</i>. Overall, our findings revealed a significant association between <i>ALKBH1</i> gene polymorphisms and hepatoblastoma susceptibility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ALKBH1 gene polymorphisms confer hepatoblastoma susceptibility in Chinese children

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月21日

查看全文
  • Chongwei He,
  • Lingling Pan,
  • Xinhao Zeng,
  • Hua Wang,
  • Zhonghua Yang,
  • Jiao Zhang,
  • Yong Li,
  • Li Li,
  • Suhong Li,
  • Jiwen Cheng,
  • Yalan Song,
  • Jing He,
  • Chaoyang Chen

摘要

Hepatoblastoma is the most common malignant liver tumor of embryonic origin in children; however, its underlying etiology remains unclear. N1-methyladenosine (m1A) modification is widely found in various human tissues and has been demonstrated to regulate tumorigenesis, but no studies have explored the role of ALKBH1 in the development of hepatoblastoma. We genotyped three ALKBH1 gene polymorphisms (rs1048147 C > A, rs6494 T > A, and rs176942 A > G) via the TaqMan method for 313 patients with hepatoblastoma and 1446 healthy subjects, after which the odds ratios (ORs), 95% confidence intervals (CIs), and P values for each polymorphism were calculated. We found that all the three polymorphisms were significantly associated with hepatoblastoma susceptibility. The rs1048147 C > A was shown to reduce hepatoblastoma risk (adjusted OR = 0.72, 95% CI = 0.56–0.92, P = 0.009) under dominant model, whereas rs6494 T > A (adjusted OR = 6.17, 95% CI = 1.37–27.37, P = 0.018) and rs176942 A > G (adjusted OR = 2.12, 95% CI = 1.22–3.69, P = 0.008) significantly increased hepatoblastoma risk under recessive model. Stratified analysis indicated that the rs1048147 CA/AA genotype decreased hepatoblastoma risk in children aged ≥ 17 months, females, and those with clinical stages I + II, whereas the rs176942 GG genotype increased the risk of hepatoblastoma in females. In addition, carriers of 2–3 risk genotypes had higher risk of tumor development, specifically among children aged ≥ 17 months, males, and those diagnosed with clinical stages I–II disease. Finally, eQTL analysis revealed that the three polymorphisms were associated with the expression levels of ADCK1, SNW1, and SLIRP. Overall, our findings revealed a significant association between ALKBH1 gene polymorphisms and hepatoblastoma susceptibility.